The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Non-Muscle Invasive Bladder Cancer Market Expected To Reach Based On Its 2026 Value?
The non-muscle invasive bladder cancer market has demonstrated strong expansion in recent years. This market is anticipated to increase from $3.66 billion in 2025 to $3.87 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The historical growth can be attributed to several factors such as the early detection of bladder cancer, continued reliance on transurethral resection, limited adoption of intravesical therapy, the development of hospital pharmacy infrastructure, and insufficient awareness of NMIBC staging.
The non-muscle invasive bladder cancer market size is projected to experience substantial growth in the upcoming years, expanding to $4.82 billion by 2030 at a compound annual growth rate (CAGR) of 5.6%. This anticipated growth is attributed to the escalating prevalence of bladder cancer, the increasing acceptance of immunotherapy and chemotherapy, the expansion of online and retail pharmacy channels, a broadening use of advanced diagnostic imaging, and evolving personalized treatment approaches. Major developments expected in the forecast period include the rising adoption of AI-powered diagnostic tools, an increased application of genomics and precision medicine strategies, the growing implementation of data-driven clinical decision support, the expanding deployment of minimally invasive therapeutic techniques, and the advancing integration of connected health monitoring solutions.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20904&type=smp
What Factors Are Contributing To The Growth Of The Non-Muscle Invasive Bladder Cancer Market?
An increasing emphasis on personalized medicine is projected to drive the expansion of the non-muscle invasive bladder cancer market in the future. This approach entails tailoring medical care according to an individual’s unique genetic makeup, way of life, and surroundings, leading to improved effectiveness. This heightened focus on personalized medicine stems from multiple factors, including breakthroughs in genomic research, enhanced diagnostic instruments, and a rising need for more precise and impactful therapies. The non-muscle invasive bladder cancer market benefits from personalized medicine through the creation of customized treatment strategies, which consider particular tumor traits, genetic indicators, and unique patient details. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that the FDA sanctioned 16 novel personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, this trend is fueling the expansion of the non-muscle invasive bladder cancer market.
How Is The Non-Muscle Invasive Bladder Cancer Market Segmented Across Different Segment Categories?
The non-muscle invasive bladder cancer market covered in this report is segmented –
1) By Stage: Carcinoma In Situ (CIS), T1 Stage, Ta Stage
2) By Treatment: Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Other Treatments
3) By Tumor: Low-Grade Tumours, High-Grade Tumours
4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS, Low-Grade CIS
2) By T1 Stage: T1a Stage (Superficial Tumors), T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage, High-Grade Ta Stage
What Trends Are Shaping The Future Of The Non-Muscle Invasive Bladder Cancer Market?
Leading firms within the non-muscle invasive bladder cancer market are prioritizing the creation of novel products, including immunotherapy, with the goal of enhancing therapeutic choices and patient results. This approach, immunotherapy, utilizes the body’s own immune system to identify and fight cancer cells through the stimulation or activation of immune reactions. As an example, in March 2024, the US biotechnology company, ImmunityBio Inc., gained Food and Drug Administration (FDA) approval for ANKTIVA (N-803) for managing patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) that includes carcinoma in situ (CIS), either with or without papillary tumors. This clearance was granted following encouraging clinical trial data, indicating that ANKTIVA, when administered alongside Bacillus Calmette-Guérin (BCG), provides an effective treatment alternative for individuals who have previously failed standard BCG therapy. ANKTIVA functions as a groundbreaking IL-15 agonist immunotherapy, operating by bolstering the immune system, particularly by activating natural killer (NK) cells and CD8+ killer T cells to pinpoint and eliminate cancer cells.
Which Organizations Play A Role In The Non-Muscle Invasive Bladder Cancer Market Landscape?
Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co Inc, AstraZeneca plc, Astellas Pharma US Inc, EMD Serono Inc, Genentech Inc, Aura Biosciences Inc, UroGen Pharma Ltd, Protara Therapeutics Inc, Istari Oncology Inc, Heat Biologics Inc, Viventia Bio Inc, ImmunityBio Inc, Altor BioScience Corporation, SURGE Therapeutics Inc, Pfizer Inc, Hoffmann‑La Roche Ltd, CG Oncology Inc, Tyra Biosciences Inc, Prokarium Ltd, ImmVira Pharma Co Ltd, Trigone Pharma Ltd, enGene Holdings Inc, Atonco Pharma Ltd.
Get The Full Non-Muscle Invasive Bladder Cancer Market Report:
Where Is The Non-Muscle Invasive Bladder Cancer Market Most Concentrated Geographically?
North America was the largest region in the non-muscle invasive bladder cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Muscle Invasive Bladder Cancer Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Muscle Invasive Bladder Cancer Market 2026, By The Business Research Company
Prenatal Testing And Newborn Screening Market Report 2026
Prenatal And Newborn Genetic Testing Market Report
Pregnancy Test Kits Market Report
https://www.thebusinessresearchcompany.com/report/pregnancy-test-kits-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model